![Frontiers | Development of a Highly Sensitive Neurofilament Light Chain Assay on an Automated Immunoassay Platform Frontiers | Development of a Highly Sensitive Neurofilament Light Chain Assay on an Automated Immunoassay Platform](https://www.frontiersin.org/files/Articles/935382/fneur-13-935382-HTML-r1/image_m/fneur-13-935382-g007.jpg)
Frontiers | Development of a Highly Sensitive Neurofilament Light Chain Assay on an Automated Immunoassay Platform
Při střelbě v centru Paříže zemřeli tři lidé, další jsou zranění. Podezřelý útočil už v minulosti | iROZHLAS - spolehlivé zprávy
![Těžký válečný zločin.“ Nemocnice zasažená americkou raketou? Moskva obvinila Kyjev | ParlamentniListy.cz – politika ze všech stran Těžký válečný zločin.“ Nemocnice zasažená americkou raketou? Moskva obvinila Kyjev | ParlamentniListy.cz – politika ze všech stran](https://cms.parlamentnilisty.cz/image.ashx?w=632&h=307&f=14_635507033242546028.jpg&id=36961)
Těžký válečný zločin.“ Nemocnice zasažená americkou raketou? Moskva obvinila Kyjev | ParlamentniListy.cz – politika ze všech stran
![Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial - The Lancet Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/2000990306/2003649239/gr1.gif)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial - The Lancet
![Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial - The Lancet Oncology Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/8ddea705-5237-43dd-b633-1d0ecf652605/gr1.jpg)
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial - The Lancet Oncology
Moskva se snaží zničit ukrajinské elektrárny. Rakety zasáhly asi 30 % energetické infrastruktury - Echo24.cz
![U Moskvy roste luxusní klinika pro kremelské prominenty. Ti kvůli sankcím nemohou na léčbu do ciziny - Aktuálně.cz U Moskvy roste luxusní klinika pro kremelské prominenty. Ti kvůli sankcím nemohou na léčbu do ciziny - Aktuálně.cz](https://cdn.xsd.cz/resize/ef090bab8cdf3b62a99f9d5dca1f7fbd_resize=560,329_.jpg?hash=e0d371de4eddcf2dc0b8327e6f183cd9)
U Moskvy roste luxusní klinika pro kremelské prominenty. Ti kvůli sankcím nemohou na léčbu do ciziny - Aktuálně.cz
![Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - The Lancet Oncology Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2045959899/2057173040/gr1.gif)